Roche Holding AG Basel American Depositary Shares (RHHBY)
$38.49 0.00 (0.00%)
16:30 EST RHHBY Stock Quote Delayed 15 Minutes
Previous Close $38.49
Market Cap 262.92B
PE Ratio -
Volume (Avg. Vol.)
Day's Range 38.49 - 38.49
52-Week Range 25.10 - 38.87
Dividend & Yield 0.92 (2.39%)
RHHBY Stock Predictions, Articles, and Roche Holding AG Basel American Depositary Shares News
- From InvestorPlace
- From the Web
One of the best mutual funds last year was the T. Rowe Price Health Sciences Fund. Here are 7 healthcare stocks to buy from its holdings.
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by....
Why NewLink Genetics Corp (NLNK), Urban Outfitters, Inc. (URBN) and Dell Technologies Inc (DVMT) Are 3 of Today’s Worst Stocks
Dell Technologies (DVMT), NewLink Genetics (NLNK) and Urban Outfitters (URBN) shareholders couldn't wait for Thursday's action to come to a close.
Biotechnology is among the most exciting and lucrative sectors for investors, and these 3 biotech stocks stand out...
The iShares MSCI EAFE ETF (EFA) holds nearly 940 stocks based outside the U.S. Is the EFA the right way to get international exposure?
I've uncovered a data set that show Switzerland as the most innovative country in the world. Here's how to take advantage...
By Richard Band
Roche has plenty of great drugs under its umbrella and RHHBY stock should do well no matter what the government decides to do.
By Richard Band
The Big Pharma is set to have a very good 2017 and put 2016 behind it.
Eleven Biotherapeutics stock soared on Monday following news of its deal with Roche concerning its Interleukin-6 technology.
Johnson & Johnson is one of the strongest dividend payers the market's have to offer. Here's why I'm willing to pay a premium to own JNJ stock
Big data can be used by big pharma companies like Roche to drastically cut costs, increase drug production and drive long-term stock gains.
The introduction of biosimilar drugs will change the biotech landscape ... especially for these three names.
Amgen, Inc. (NASDAQ:AMGN), Celgene Corporation (NASDAQ:CELG), Inovio Pharmaceuticals Inc. (NASDAQ:INO) and several other healthcare stocks are cancer medicine plays worth a look.
Ebola stocks have doled out some big gains to savvy traders this year, but investors looking for Roche (RHHBY) to do the same may want to rethink their expectations.
Roche stock may not be an NYSE or NASDAQ-listed equity, but when you look at the details, RHHBY is plenty investment-worthy.
Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities
The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint